Background
==========

Acute appendicitis is one of the most common urgent conditions seen in general surgery practice. Complications can be severe and include perforation and generalised peritonitis. Traditionally, surgical appendectomy has been the primary treatment, even in cases of unconfirmed diagnosis, given the low incidence of major complications. However, in 15--30% of cases the appendix is found to be free of disease upon resection.[@b1] [@b2] As appendectomy is associated with surgical wound infection, intestinal obstruction due to adhesions, pneumonia, and tubal infertility in females, the possibility of using conservative treatment merits investigation.

Non-operative treatment of a suspected appendicitis has safety implications. Delaying surgery may increase the risk of perforated appendicitis, intra-abdominal abscesses, and localised or diffuse peritonitis before surgery and wound infection, increased risk of adhesions and subsequent adhesive small bowel obstruction (ASBO) and infertility after surgery. Anaesthesia carries its own risks, and there can also be intraoperative (vascular lesions, enterotomies, urinary tract lesions, etc), early surgical postoperative (haematoma/bleeding, colonic fistula, surgical site infection (SSI), intra-abdominal abscess, adhesions and ileus/obstruction) with subsequent re-operation, late surgical postoperative (adhesions and subsequent ASBO and tubal infertility, incisional hernias) and general postoperative complications.

Surgery may be associated with a longer hospital stay and higher costs compared with NOM with antibiotics, but delayed treatment and a perforated appendix may worsen morbidity, duration of sick leave and costs. However, NOM with antibiotics may be a cost-effective alternative to surgery in a large percentage of patients without increasing the risk, and may reduce hospital stay and costs in both developed and third world countries.

There is considerable debate regarding the utility of conservative treatment compared with surgical treatment in some cases of acute appendicitis, as few studies have addressed this issue to date.[@b3; @b4; @b5] If conservative treatment is to be considered, it will be very importance to make an accurate diagnosis and assessment in every patient in order to select the most appropriate treatment.

The idea that appendicitis may resolve spontaneously is not new. In 1908 Alfred Stengel wrote: "Treated in a purely medical or tentative manner, the great majority of patients with appendicitis recover".[@b6]

Restrained indications with few negative appendectomies are associated with a low incidence of diagnosed non-perforated appendicitis and a secondary high proportion of perforated appendicitis, but no increase in the incidence of perforations.[@b7] This suggests that appendicitis in a significant number of patients may resolve undiagnosed. Resolving appendicitis may also be indicated by a history of recurrent appendicitis, which can be found in up to 6.5% of patients operated on for appendicitis.[@b8]

When perforation results from delayed treatment, the associated increase in morbidity and mortality must be weighed against the risks of a negative appendectomy. The excess mortality associated with non-perforated appendicitis and with negative appendectomy with a discharge diagnosis of non-specific abdominal pain, suggests that appendectomy itself carries risks. The decrease in mortality that may be achieved by one prevented perforation is therefore negated by each negative appendectomy.[@b9] [@b10]

Other reports indicate that immediate appendectomy can be avoided for at least 24 h without increasing morbidity if antibiotics are administered.[@b11] Other authors suggest that appendectomy may not be necessary for the majority of patients with acute uncomplicated appendicitis, as the condition resolves spontaneously in many patients and in others may be treatable with antibiotics alone.[@b12] This approach has many advantages, including high success and low recurrence rates, reduced morbidity and mortality, less pain, shorter hospitalisation and sick leave, and reduced costs.[@b13]

In light of this, routine interval appendectomy after initial successful conservative treatment does not seem justified and should be abandoned. In fact, traditional interval appendectomy may prevent recurrent appendicitis in only 6.7% of patients after conservative treatment of acute appendicitis with an appendiceal mass. Thus 93.3% would have an unnecessary appendectomy.[@b14]

A recent meta-analysis comparing conservative treatment with acute appendectomy for complicated appendicitis (abscess or phlegmon) and including 1572 patients (847 patients received conservative treatment and 725 had acute appendectomy) showed that conservative treatment was associated with significantly fewer overall complications, wound infections, abdominal/pelvic abscesses, ileus/bowel obstructions and re-operations. Furthermore, there were significantly fewer overall complications in conservative treatment groups during sensitivity analysis of studies including only paediatric patients, high-quality studies, more recent studies, and studies with larger groups of patients.[@b15]

In particular, a randomised clinical trial (RCT) of antibiotic therapy versus appendicectomy as primary treatment of acute appendicitis in unselected patients showed that treatment efficacy was 90.8% for antibiotic therapy and 89.2% for surgery. In this trial minor complications were similar between the groups, while major complications were threefold higher in patients who had an appendicectomy (p\<0.050). In total, 2.9% of the operated patients underwent a second operation, 3% of them developed abscesses, 2.4% postoperative small bowel obstruction (SBO), 1.8% wound rupture or wound hernia, 0.6% pulmonary embolism and 0.6% postoperative cardiac complications, and 1.2% underwent subsequent ileocaecal resection. Wound infection occurred in 7.6% and 1.2% of the patients had anaesthesia-related problems.[@b16]

In another RCT comparing appendectomy with antibiotic treatment in acute appendicitis, the complication rate in the surgery group was 14% (17/124) and was mainly due to wound infections. In the surgery group, time in hospital, sick leave taken and time lost from work were respectively 2.6, 6.0 and 10.1 days.[@b5]

The cumulated risk of surgically treated SBO after appendicectomy was 0.41% after 4 weeks, 0.63% after 1 year and 1.30% after 30 years of follow-up, compared with 0.003% at 1 year and 0.21% after 30 years of follow-up among non-operated controls, with perforated appendicitis, negative appendicectomy and high age risk factors for developing subsequent SBO.[@b17]

A further paper reviewing 1777 patients who underwent appendectomy for acute appendicitis, showed the overall SBO rate to be 2.8% over an average 4.1-year follow-up period or 0.0069 cases per person-year.[@b18]

The laparoscopic approach also carries risks, including intraoperative complications ranging from 3.1% to 0.7%, surgical postoperative complications ranging from 6.1% to 1.9%, general postoperative complications ranging from 4.9% to 1.5% and rates of re-operations ranging from 3.4% to 0.7%.[@b19]

A comparison of 3025 open versus 14 174 laparoscopic appendectomies showed SSI occurred in 4% and 1.2%, deep incisional wound infection in 1.2% and 0.2%, wound disruption in 0.3% and 0.1%, organ space infection in 1.3% and 1.7%, pneumonia in 0.6% and 0.3%, renal failure in 0.2% and 0.3%, urinary tract infection (UTI) in 0.5% and 0.4%, deep vein thrombosis in 0.4% and 0.1%, sepsis in 1.4% and 1.0% and septic shock 0.3% and 0.1%, respectively. Appendectomy may also be associated with mortality (0.3% for open and 0.1% for laparoscopic).[@b20]

Another large population based appraisal including 32 683 patients reported morbidity and mortality for both open and laparoscopic appendectomy.[@b21] Overall morbidity was 8.84% and 4.46%, respectively, serious morbidity 4.23% and 2.58%, SSI 6.65% and 3.26%, serious morbidity/mortality 4.26% and 2.60%, and mortality 0.13% and 0.07%. Superficial SSI incidence was, respectively, 3.89% and 1.26%, deep incisional SSI 0.99% and 0.24%, organ space SSI 1.72% and 1.79%, wound disruption 0.45% and 0.06%, pneumonia 0.43% and 0.24%, pulmonary embolism 0.08% in both open and lap groups, sepsis or septic shock 2.16% and 1.15%, bleeding 0.01 and 0.04% and UTIs 0.36% and 0.37%.

The long term follow-up of a RCT of open versus laparoscopic appendicectomy showed a 42.3% incidence of overall complications in the open surgery group versus 12.8% in the laparoscopic group, with wound-related complications as high as 30.77% versus 4.2%.[@b22] After a mean follow-up of more than 9 years, 5.7% and 6.4% of patients, respectively, had adhesions or adhesion-related symptoms and 0.2% underwent another operation for adhesions. The risk of SBO after open appendectomy is between 0.33 and 1.51%.

Finally, it has been demonstrated that a history of perforated appendix in childhood does not seem to have long term negative consequences on female fertility. This may have important implications for the management of young women with suspected appendicitis as the liberal attitude to surgical exploration with a subsequently high rate of removal of a normal appendix is no longer justified by a perceived increased risk of infertility after perforation.[@b23]

In addition, a liberal attitude to exploration among patients with suspected appendicitis does not prevent perforations.[@b24]

Hansson *et al*[@b16] conducted a RCT investigating the efficacy of conservative treatment compared to surgery for acute appendicitis. They reported that conservative treatment with antibiotics was efficacious in 91% of cases, with a 14% relapse rate at 12-month follow-up. One third of relapses occurred within the first 10 days of hospital discharge, while most of the remaining two thirds occurred between 3 and 16 months following discharge. The rates of minor complications such as diarrhoea, vomiting and nosocomial infections were similar among patients treated conservatively and those treated surgically. The incidence of major complications such as appendiceal abscess, paralytic ileus and pulmonary embolism, however, was significantly higher in those treated surgically (p\<0.05).

A recent prospective randomised study conducted by Malik A and colleagues[@b1] compared antibiotic therapy to appendectomy in acute appendicitis. The authors reported that conservative treatment was not only safe and efficacious, but also caused the patients less pain than surgery, reducing the need for analgesia (p\<0.001). Ten per cent of conservatively treated patients relapsed within 12 months of discharge.

A multicentre randomised trial conducted in Sweden[@b16] yielded similar results: the rate of relapse in antibiotic treated patients was 14% at 1 year after discharge. Interestingly, this was equal to the rate of post-operative complications in patients treated surgically.

Based on these reports, with the diagnostic accuracy of acute appendicitis being as high as 71%--87% with a combination of modern preoperative investigations,[@b25] conservative treatment with antibiotics seems to valid for cases of suspected or probable/proven acute appendicitis. Relapse rate is low and complications are no higher than the rate of surgical complications.

Rationale
=========

Case control studies that randomly assign patients with suspected acute appendicitis to either surgical or non-surgical treatment show a relapse rate of approximately 14% at 1 year. It would, therefore, be useful to determine the relapse rate of patients treated according to the results of a thorough clinical evaluation, including physical examination and laboratory results (all characteristics used to determine the Alvarado score[@b26]) as well as radiological evaluation. Imaging such as ultrasound may be helpful but is not usually necessary in diagnosing acute appendicitis and deciding its further treatment (operative or non-operative). As the Alvarado and AIR[@b27] scores are based only on clinical and laboratory characteristics, only clinical signs and symptoms and laboratory values are routinely evaluated in patient with suspected acute appendicitis. If this clinical evaluation is effective, we would expect patient selection to be better than chance, and the relapse rate to be below 14%. Once we have established the utility of this evaluation, we can begin to identify those components that have predictive value (such as blood chemistry analysis or CT findings). This would be a first step towards developing an accurate diagnostic--therapeutic algorithm which could be used to avoid the risks and costs of needless surgery.

Much research into the cause of diseases relies on cohort, case--control or cross-sectional studies. Observational studies also have a role in research into the benefits and harms of medical interventions. Randomised trials cannot answer all important questions about a given intervention. For example, observational studies are more suitable for detecting rare or late adverse effects of treatments, and are more likely to provide an indication of what is achieved in daily medical practice.[@b28]

Study description
=================

This will be a single-cohort prospective observational study. Patients presenting to the emergency department will undergo some or all of the following tests: complete blood count with differential, C reactive protein, abdominal ultrasound and abdominal CT scan. Patients with lower abdominal pain and suspicion of acute appendicitis not requiring immediate surgery, will be requested to undergo observation and non-operative treatment with antibiotic therapy (amoxicillin and clavulanic acid) and provide informed consent.

Suspected acute appendicitis is defined as patient presenting with right iliac fossa (RIF) pain AND absence of a definite alternative diagnosis, either of a gastrointestinal disease (such as inflammatory bowel disease (IBD), irritable bowel syndrome, colitis, etc) or urinary tract disease (such as UTI, renal colic, urinary tract stones, etc) or an obstetric-gynaecological cause (such as pregnancy, pelvic inflammatory disease, ovulation, etc).

Patients needing immediate surgery are defined as those with diffuse peritonitis and/or signs of sepsis, as well as patients with clinico-radiological (US or CT scan) evidence of an intra-abdominal collection/abscess.

The patients by protocol should not have received any previous antibiotic treatment during the same clinical episode. Patients not undergoing surgery will be physically examined 5 days later. If their condition has not improved or worsened, they will be admitted for surgical appendectomy. If they have improved, they will be given information about the study and invited to participate, and asked to sign an informed consent form for further follow-up. If the patient is under the age of 18 years, consent will be obtained from a parent or other legal guardian.

Telephone (or email) follow-up will be conducted at 7 and 15 days, 6 months and 1 year (see [figure 1](#fig1){ref-type="fig"}). In the case of patients under the age of 18 years, the phone interview will be conducted with a parent or legal guardian. The patient will be asked if he/she has undergone surgery since the first visit (5 days after presenting to the emergency department). If not, the patient will be asked:

1.  Has your illness improved, stayed the same, or worsened since its onset?

2.  Have you undergone any further tests or had additional doctor\'s visits for your illness?

3.  After your initial emergency department visit, how long did it take to return to your normal activities (physical activity, work, etc)?

![Non-operative treatment for acute appendicitis: patient outcomes and follow-up in a single-cohort prospective observational study. Flow diagram of the study according to CONSORT 2010.](bmjopen-2010-000006fig1){#fig1}

Statistical analysis
====================

Data will be entered into a spreadsheet using Epi-Info (v 6.04d, Centers for Disease Control and Prevention) and analysed using SPSS software (v 15.0, SPSS). Descriptive statistics will be reported as mean and SD for normally distributed variables and median and IQR for variables not normally distributed. The χ^2^ analysis of variance will be used to compare differences for categorical variables. ORs with 95% CIs will be calculated. Student\'s paired sample t test will be used to compare mean differences between continuous variables. The Mann--Whitney U test will be used to compare non-parametric continuous variables (eg, age, white cell count). Statistical significance will be defined as p\<0.05. Variables with clinically relevant cut-off points will be dichotomised.

In order to determine independent predictors of the short and long term efficacy of antibiotic treatment (in terms of failure rate of conservative treatment, recurrence rate of clinical episodes of acute appendicitis and definite improvement without need for surgery within 1 year of follow-up) in the general study population, numerous variables will be assessed including demographic characteristics (sex, age), clinical features (past medical history, gynaecological status, IBD history), clinical status (body temperature), laboratory studies (white cell count, neutrophils count, C reactive protein), whether or not empiric antibiotics were previously administered, and time to administration and duration of treatment with amoxicillin and clavulanic acid.

Univariate analyses will be used to identify which variables with a p value less than 0.20 should be included in the multivariate models. Stepwise backward logistic regression will be used to determine whether these covariates are independent predictors of treatment efficacy; covariates will be eliminated when p values are greater than or equal to 0.05.

The same methods will be used to assess predictors of abdominal pain after discharge, length of hospital stay, number of outpatient clinic follow-up appointments and sick leave.

Finally, cost analysis will be carried out on antibiotic course, length of hospital stay, outpatient clinic follow-up appointments and sick leave days.

Study objectives
================

Main objective
--------------

The main objective is to evaluate the outcome of patients treated conservatively and assess the reliability of the initial clinical evaluation in predicting which conservatively-treated patients should have been treated surgically.

The primary outcomes are:

1.  Short term efficacy of antibiotic treatment: failure of conservative treatment with 7 days of amoxicillin and clavulanic acid therapy, defined as readmission due to lack of clinical improvement and/or worsening abdominal pain and/or localised/diffuse peritonitis.

2.  Long term efficacy of antibiotic treatment: efficacy of antibiotic therapy for acute appendicitis defined as incidence of recurrences of clinical episodes of appendicitis up to follow-up at 1 year (at 7 days, 15 days, 6 months, 1 year).

3.  Long term efficacy of antibiotic treatment (no need for surgery): efficacy of antibiotic therapy for acute appendicitis defined as definite improvement without the need for surgery up to follow-up at 1 year (at 7 days, 15 days, 6 months, 1 year).

4.  Safety of antibiotic treatment: major side effects/drug- or treatment-related complications (ie, allergy or other treatment-related complications such as abscess formation).

The secondary outcomes are:

1.  Minor complications: minor side effects/drug- or treatment-related complications (ie, bloating, diarrhoea, flatulence, headache, heartburn, nausea and vomiting) (at 7 days, 15 days).

2.  Abdominal pain after discharge: assessment of abdominal pain/discomfort evaluated by means of a numerical rating scale (at 7 days, 15 days).

3.  Length of hospital stay: length of clinical observation as an inpatient for non-operated patients.

4.  Outpatient clinic follow-up: number of follow-up appointments scheduled in the outpatient clinic.

5.  Sick leave: number of days of sick leave needed by the patient.

6.  Cost analysis: analysis of the costs of antibiotics, length of hospital stay, outpatient clinic follow-up appointments and sick leave days.

Secondary objective
-------------------

An additional objective is to identify clinical, laboratory and imaging findings that are predictive of failure of conservative treatment and/or relapse of appendicitis and need for appendectomy within 1 year.

Study design
============

This is a single cohort prospective non-randomised observational study. No experimental interventions or treatments will be employed beyond routine clinical care.

A flowchart of the study is given in [figure 2](#fig2){ref-type="fig"} and a tempogram showing the study steps is given in [figure 1](#fig1){ref-type="fig"}.
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Estimated enrolment and study dates
===================================

The estimated sample size of the study population is 160 patients in 1 year, which is the average number of patients assessed annually by the emergency surgical team in our hospital for suspected acute appendicitis, conservatively treated with antibiotics and observed. The crude incidence of acute appendicitis is 86 per 100 000 inhabitants per year, varying between 74 and 96 per 100 000 during a 5-year period in Norway in an urban and rural catchment area with 265 000 inhabitants. A peak incidence of acute appendicitis was found in patients 13--40 years of age, with more males than females in this age group (ratio 1.34:1.00). Among young children and the elderly, significantly (p=0.002) more females had acute appendicitis.[@b29] A further paper reported the incidence of appendicitis to be about 100 per 100 000 person-years in Europe/America.[@b30]

The appendectomy rate continues to decrease, although the incidence of appendicitis is now nearly stable and the incidence of perforated appendicitis has not changed (approximately 20 per 100 000 person-years) over the last 30 years. These data suggest the rate of surgery for acute appendicitis is decreasing in an attempt to avoid unnecessary appendectomies.

The catchment population of Bologna is half a million people. Maggiore Hospital is the largest hospital in the city and covers the northern area. The numbers of patients aged over 14 years admitted to the emergency department with right iliac fossa pain and/or suspected appendicitis have been monitored for the last 3 years and range from 328 to 443 cases/year.

The study start date is January 2010, the estimated study completion date is December 2010 and the estimated primary date of completion of follow-up is December 2011 (the final data collection date for all primary outcome measures and 1 year follow-up).

Inclusion and exclusion criteria
================================

Any patient, male or female, above the age of 14 years (non-paediatric), who returns for a follow-up visit 5 days after an emergency department visit and consents to participation between 1 January 2010 and 31 December 2010 will be eligible for inclusion in the study.

Specifically, the inclusion criteria are:

1.  Age \>14 years

2.  Lower/right iliac fossa abdominal pain

3.  Clinical suspicion of acute appendicitis, that is:

    1.  --Alvarado score 5--6 (equivocal for acute appendicitis)

    2.  --Alvarado score 7--8 (probable appendicitis)

    3.  --Alvarado score 9--10 (highly probable appendicitis)

4.  Informed consent (patient or legal representative).

Exclusion criteria are:

1.  Diffuse peritonitis

2.  Antibiotic (penicillin) documented allergy

3.  Ongoing previously commenced antibiotic therapy

4.  Previous appendectomy

5.  Positive pregnancy test

6.  IBD history or suspicion of IBD reoccurrence.

Follow-up assessment will be by telephone interview (or email). No interviewer training will be necessary as the surgeons conducting the study will also conduct the phone interviews. Informed consent will be obtained from the patient (or guardian) before enrolling him/her in the study. Confidentiality of personal and health information will be guaranteed and will only be accessible to the surgeons responsible for the study. Members of the project management team are as follows: study chair: Gregorio Tugnoli, MD; principal investigators: Salomone Di Saverio MD, Eleonora Giorgini MD, Nicola Antonacci, MD, Andrea Biscardi, MD, Nicola Clemente MD and Silvia Villani MD. The over-seeing authority is the Bologna Local Health District Ethics Committee (approval number CE 09079). The study follows the recommendations of the Declaration of Helsinki[@b31] and conforms with the accepted best practice guidelines of the STROBE statement for observational studies (cohort, case--control or cross-sectional designs)[@b32] ([table 1](#tbl1){ref-type="table"}).
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